Evidence map›Paper›PMID 36922677›Full record

ArticleOncogene2023

LncRNA XIST regulates breast cancer stem cells by activating proinflammatory IL-6/STAT3 signaling.

Yuxi Ma, Yongyou Zhu, Li Shang, Yan Qiu, Na Shen, Jonathan Wang, Tiffany Adam, Wei Wei, Qingxuan Song, Jun Li and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogene, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 1 pooled it
15.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Yuxi Ma *Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA.
Yongyou Zhu *Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA.
Li Shang *Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA.
Yan QiuDepartment of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA.
Na ShenDepartment of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA.
Jonathan WangDepartment of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA.
Tiffany AdamDepartment of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA.
Wei WeiDepartment of Breast and Thyroid Surgery, Peking University Shenzhen Hospital, Shenzhen, 518036, China.
Qingxuan SongDepartment of Human Genetics, University of Michigan Medical School, Ann Arbor, MI, 48109, USA.
Jun LiDepartment of Human Genetics, University of Michigan Medical School, Ann Arbor, MI, 48109, USA.
Max S WichaDepartment of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA. mwicha@med.umich.edu.ORCID 0000-0003-4180-7727
Ming LuoDepartment of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA. mingluo@med.umich.edu.ORCID 0000-0002-0795-3678
University of Michigan · USUnion Hospital · CNPeking University Shenzhen Hospital · CN

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Eric R. Fearon · 1988 to 2026
$178.2M
Targeting breast cancer stem cellsR35CA197585 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI WICHA, MAX S. · 2016 to 2022
$6.4M
High-resolution map of human germline mutation patterns and inference of mutagenic mechanismsR01GM118928 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LI, JUN, ZOELLNER, SEBASTIAN · 2016 to 2019
$1.2M
NCI NIH HHS P30 CA046592NCI NIH HHS R35 CA197585NIGMS NIH HHS R01 GM118928
6 · The paper itself

Abstract

Aberrant expression of XIST, a long noncoding RNA (lncRNA) initiating X chromosome inactivation (XCI) in early embryogenesis, is a common feature of breast cancer (BC). However, the roles of post-XCI XIST in breast carcinogenesis remain elusive. Here we identify XIST as a key regulator of breast cancer stem cells (CSCs), which exhibit aldehyde dehydrogenase positive (ALDH

Indexed as

Breast NeoplasmsRNA, Long NoncodingTriple Negative Breast NeoplasmsAldehyde DehydrogenaseCell Line, TumorFemaleHumansInterleukin-6Neoplastic Stem CellsPhenotypeSignal TransductionSTAT3 Transcription FactorAldehyde DehydrogenaseInterleukin-6RNA, Long NoncodingSTAT3 protein, humanSTAT3 Transcription Factor

Identifiers

PMID36922677
PMCPMC10154203
OpenAlexW4324351612

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.